{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:00:51Z","timestamp":1790614851901,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The financial implications of Lyme disease (LD) can vary widely for both the health system and the individual patients experiencing the disease. The aim of this review was to summarize published data on clinical and economic outcomes associated with LD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A literature review was conducted to identify all studies of LD that incorporate both clinical outcomes and costs. Included studies were described and categorized based on costs consistent with best practices used in economic evaluation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The most frequent costs identified focused on formal health costs and productivity losses were the most common costs identified outside of the health system. Travel and informal care costs were less frequently reported. Clinical and economic outcomes of LD are primarily studied through economic models or observational analyses and focus on formal health care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This review provides and overview of existing evidence and recommendations for future economic analyses in LD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13071-020-04214-y","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T08:08:50Z","timestamp":1594282130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical and economic outcomes evaluated in Lyme disease: a systematic review"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-5780","authenticated-orcid":false,"suffix":"II","given":"T. Joseph","family":"Mattingly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Shere-Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"4214_CR1","unstructured":"Centers for Disease Control and Prevention. Lyme disease. Centers for Disease Control and Prevention; 2019. https:\/\/www.cdc.gov\/lyme\/index.html. Accessed 13 Jan 2019."},{"key":"4214_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"GP Wormser","year":"2006","unstructured":"Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089\u2013134.","journal-title":"Clin Infect Dis."},{"key":"4214_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/jac\/dkq097","volume":"65","author":"S Warshafsky","year":"2010","unstructured":"Warshafsky S, Lee DH, Francois LK, Nowakowski J, Nadelman RB, Wormser GP. Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis. J Antimicrob Chemother. 2010;65:1137\u201344.","journal-title":"J Antimicrob Chemother."},{"key":"4214_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1001\/jama.2016.2884","volume":"315","author":"E Sanchez","year":"2016","unstructured":"Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315:1767\u201377.","journal-title":"JAMA."},{"key":"4214_CR5","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/j.ijid.2013.01.008","volume":"17","author":"JN Aucott","year":"2013","unstructured":"Aucott JN, Crowder LA, Kortte KB. Development of a foundation for a case definition of post-treatment Lyme disease syndrome. Int J Infect Dis. 2013;17:e443\u20139.","journal-title":"Int J Infect Dis."},{"key":"4214_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2296-15-79","volume":"15","author":"A Ali","year":"2014","unstructured":"Ali A, Vitulano L, Lee R, Weiss TR, Colson ER. Experiences of patients identifying with chronic Lyme disease in the healthcare system: a qualitative study. BMC Fam Pract. 2014;15:79.","journal-title":"BMC Fam Pract."},{"key":"4214_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-015-0325-4","volume":"34","author":"E Onukwugha","year":"2015","unstructured":"Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2015;34:43\u201358.","journal-title":"Pharmacoeconomics."},{"key":"4214_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","volume":"29","author":"A Larg","year":"2011","unstructured":"Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653\u201371.","journal-title":"Pharmacoeconomics."},{"key":"4214_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40273-016-0438-4","volume":"34","author":"TJ Mattingly II","year":"2016","unstructured":"Mattingly TJ II, Mullins CD, Onukwugha E. Publication of cost-of-illness studies: does methodological complexity matter? Pharmacoeconomics. 2016;34:1067\u201370.","journal-title":"Pharmacoeconomics."},{"key":"4214_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/ip.6.3.177","volume":"6","author":"DP Rice","year":"2000","unstructured":"Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177\u20139.","journal-title":"Inj Prev."},{"key":"4214_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2165\/00019053-200119020-00007","volume":"19","author":"BS Bloom","year":"2001","unstructured":"Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics. 2001;19:207\u201313.","journal-title":"Pharmacoeconomics."},{"key":"4214_CR12","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1586\/14760584.2015.1091313","volume":"14","author":"R \u0160mit","year":"2015","unstructured":"\u0160mit R, Postma MJ. Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics. Expert Rev Vaccines. 2015;14:1549\u201361.","journal-title":"Expert Rev Vaccines."},{"key":"4214_CR13","doi-asserted-by":"publisher","first-page":"e0210280","DOI":"10.1371\/journal.pone.0210280","volume":"14","author":"S Mac","year":"2019","unstructured":"Mac S, da Silva SR, Sander B. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: a scoping review. PLoS ONE. 2019;14:e0210280.","journal-title":"PLoS ONE."},{"key":"4214_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med."},{"key":"4214_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses. JAMA. 2016;316:1093\u2013103.","journal-title":"JAMA."},{"key":"4214_CR16","doi-asserted-by":"publisher","first-page":"e0195260","DOI":"10.1371\/journal.pone.0195260","volume":"13","author":"A Berende","year":"2018","unstructured":"Berende A, Nieuwenhuis L, Ter Hofstede HJM, Vos FJ, Vogelaar ML, Tromp M, et al. Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease. PLoS ONE. 2018;13:e0195260.","journal-title":"PLoS ONE."},{"key":"4214_CR17","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.7717\/peerj.322","volume":"2","author":"L Johnson","year":"2014","unstructured":"Johnson L, Wilcox S, Mankoff J, Stricker RB. Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey. PeerJ. 2014;2:e322.","journal-title":"PeerJ."},{"key":"4214_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0033-3506(03)00067-2","volume":"117","author":"AWL Joss","year":"2003","unstructured":"Joss AWL, Davidson MM, Ho-Yen DO, Ludbrook A. Lyme disease\u2014what is the cost for Scotland? Public Health. 2003;117:264\u201373.","journal-title":"Public Health."},{"key":"4214_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1089\/vbz.2013.1365","volume":"13","author":"PM Lantos","year":"2013","unstructured":"Lantos PM, Brinkerhoff RJ, Wormser GP, Clemen R. Empiric antibiotic treatment of Erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling study. Vector Borne Zoonotic Dis. 2013;13:877\u201383.","journal-title":"Vector Borne Zoonotic Dis."},{"key":"4214_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.7326\/0003-4819-119-6-199309150-00010","volume":"119","author":"RW Lightfoot Jr","year":"1993","unstructured":"Lightfoot RW Jr, Luft BJ, Rahn DW, Steere AC, Sigal LH, Zoschke DC, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: a cost-effectiveness analysis. Ann Intern Med. 1993;119:503\u20139.","journal-title":"Ann Intern Med."},{"key":"4214_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ttbdis.2014.09.004","volume":"6","author":"B Lohr","year":"2015","unstructured":"Lohr B, M\u00fcller I, Mai M, Norris DE, Sch\u00f6ffski O, Hunfeld K-P. Epidemiology and cost of hospital care for Lyme borreliosis in Germany: lessons from a health care utilization database analysis. Ticks Tick Borne Dis. 2015;6:56\u201362.","journal-title":"Ticks Tick Borne Dis."},{"key":"4214_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1056\/NEJM199208203270806","volume":"327","author":"D Magid","year":"1992","unstructured":"Magid D, Schwartz B, Craft J, Schwarts JS. Prevention of Lyme disease after tick bites: a cost-effectiveness analysis. N Engl J Med. 1992;327:534\u201341.","journal-title":"N Engl J Med."},{"key":"4214_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3201\/eid0503.990302","volume":"5","author":"M Meltzer","year":"1999","unstructured":"Meltzer M, Dennis D, Orloski K. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis. 1999;5:321\u20138.","journal-title":"Emerg Infect Dis."},{"key":"4214_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/0003-4819-128-1-199801010-00007","volume":"128","author":"G Nichol","year":"1998","unstructured":"Nichol G, Dennis DT, Steere AC, Lightfoot R, Wells G, Shea B, et al. Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis. Ann Intern Med. 1998;128:37\u201348.","journal-title":"Ann Intern Med."},{"key":"4214_CR25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/archinte.161.4.554","volume":"161","author":"NA Shadick","year":"2001","unstructured":"Shadick NA, Liang MH, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med. 2001;161:554\u201361.","journal-title":"Arch Intern Med."},{"key":"4214_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/eurpub\/ckw269","volume":"27","author":"CC van den Wijngaard","year":"2017","unstructured":"van den Wijngaard CC, Hofhuis A, Wong A, Harms MG, de Wit GA, Lugn\u00e9r AK, et al. The cost of Lyme borreliosis. Eur J Public Health. 2017;27:538\u201347.","journal-title":"Eur J Public Health."},{"key":"4214_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/2374373517736385","volume":"5","author":"CR Boudreau","year":"2017","unstructured":"Boudreau CR, Lloyd VK, Gould ON. Motivations and experiences of Canadians seeking treatment for Lyme disease outside of the conventional Canadian health-care system. J Patient Exp. 2017;5:120\u20136.","journal-title":"J Patient Exp."},{"key":"4214_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3201\/eid1204.050602","volume":"12","author":"X Zhang","year":"2006","unstructured":"Zhang X, Meltzer MI, Pe\u00f1a CA, Hopkins AB, Wroth L, Fix AD. Economic impact of Lyme disease. Emerg Infect Dis. 2006;12:653\u201360.","journal-title":"Emerg Infect Dis."},{"key":"4214_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S0149-2918(98)80081-7","volume":"20","author":"E Maes","year":"1998","unstructured":"Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther. 1998;20:993\u20131008.","journal-title":"Clin Ther."},{"key":"4214_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.0737-1209.2006.230104.x","volume":"23","author":"D Drew","year":"2006","unstructured":"Drew D, Hewitt H. A qualitative approach to understanding patients\u2019 diagnosis of Lyme disease. Public Health Nurs. 2006;23:20\u20136.","journal-title":"Public Health Nurs."},{"key":"4214_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199707313370525","volume":"337","author":"MH Eckman","year":"1997","unstructured":"Eckman MH, Steere AC, Kalish RA, Pauker SG. Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis. N Engl J Med. 1997;337:357\u201363.","journal-title":"N Engl J Med."},{"key":"4214_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jama.279.3.206","volume":"279","author":"AD Fix","year":"1998","unstructured":"Fix AD, Strickland GT, Grant J. Tick bites and Lyme disease in an endemic: setting problematic use of serologic testing and prophylactic antibiotic therapy. J Am Med Assoc. 1998;279:206\u201310.","journal-title":"J Am Med Assoc."},{"key":"4214_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12875-017-0636-y","volume":"18","author":"S Gasmi","year":"2017","unstructured":"Gasmi S, Ogden NH, Leighton PA, Adam-Poupart A, Milord F, Lindsay LR, et al. Practices of Lyme disease diagnosis and treatment by general practitioners in Quebec, 2008\u20132015. BMC Fam Pract. 2017;18:65.","journal-title":"BMC Fam Pract."},{"key":"4214_CR34","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1469-0691.2009.03059.x","volume":"16","author":"AJ Henningsson","year":"2010","unstructured":"Henningsson AJ, Malmvall BE, Ernerudh J, Matussek A, Forsberg P. Neuroborreliosis\u2014an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden. Clin Microbiol Infect. 2010;16:1245\u201351.","journal-title":"Clin Microbiol Infect."},{"key":"4214_CR35","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/art.10270","volume":"46","author":"EC Hsia","year":"2002","unstructured":"Hsia EC, Chung JB, Schwartz JS, Albert DA. Cost-effectiveness analysis of the Lyme disease vaccine. Arthritis Rheum. 2002;46:1651\u201360.","journal-title":"Arthritis Rheum."},{"key":"4214_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.healthpol.2011.05.007","volume":"102","author":"L Johnson","year":"2011","unstructured":"Johnson L, Aylward A, Stricker RB. Healthcare access and burden of care for patients with Lyme disease: a large United States survey. Health Policy. 2011;102:64\u201371.","journal-title":"Health Policy."},{"key":"4214_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force Report [3]. Value Health. 2018;21:131\u20139.","journal-title":"Value Health"},{"key":"4214_CR38","doi-asserted-by":"publisher","first-page":"e0116767","DOI":"10.1371\/journal.pone.0116767","volume":"10","author":"ER Adrion","year":"2015","unstructured":"Adrion ER, Aucott J, Lemke KW, Weiner JP. Health care costs, utilization and patterns of care following Lyme disease. PLoS ONE. 2015;10:e0116767.","journal-title":"PLoS ONE."},{"key":"4214_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40273-018-0730-6","volume":"37","author":"WBF Brouwer","year":"2018","unstructured":"Brouwer WBF. The inclusion of spillover effects in economic evaluations: not an optional extra. Pharmacoeconomics. 2018;37:451\u20136.","journal-title":"Pharmacoeconomics."},{"key":"4214_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s40273-019-00788-3","volume":"37","author":"P-J Lin","year":"2019","unstructured":"Lin P-J, D\u2019Cruz B, Leech AA, Neumann PJ, Sanon Aigbogun M, Oberdhan D, et al. Family and caregiver spillover effects in cost-utility analyses of Alzheimer\u2019s disease interventions. Pharmacoeconomics. 2019;37:597\u2013608.","journal-title":"Pharmacoeconomics."},{"key":"4214_CR41","doi-asserted-by":"publisher","first-page":"e0143875","DOI":"10.1371\/journal.pone.0143875","volume":"10","author":"D Slunge","year":"2015","unstructured":"Slunge D. The willingness to pay for vaccination against tick-borne encephalitis and implications for public health policy: evidence from Sweden. PLoS ONE. 2015;10:e0143875.","journal-title":"PLoS ONE."},{"key":"4214_CR42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10640-017-0142-7","volume":"70","author":"K Berry","year":"2018","unstructured":"Berry K, Bayham J, Meyer SR, Fenichel EP. The allocation of time and risk of Lyme: a case of ecosystem service income and substitution effects. Environ Resour Econ. 2018;70:631\u201350.","journal-title":"Environ Resour Econ."},{"key":"4214_CR43","volume-title":"Cost-effectiveness in health and medicine","author":"PJ Neumann","year":"2017","unstructured":"Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2017.","edition":"2"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-020-04214-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:20:58Z","timestamp":1650536458000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-04214-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4214"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-04214-y","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TJM reports personal fees from Bristol-Myers Squibb, the National Health Council and the Massachusetts Health Policy Commission for work unrelated to this research. KS-W declares that she has no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"341"}}